EUCTR2005-005093-70-DE进行中（未招募）不适用
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Lipid-Altering Efficacy, Safety and Tolerability of MK-0524A in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia - MK-0524A Lipid/Flushing Study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,620
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patient has a history of primary hypercholesterolemia or mixed hyperlipidemia.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patient has a history or current evidence of any condition, therapy, or lab abnormality that might confound the results of the study, interfere with the patient’s participation for the full duration of the study, or is not in the best interest of the patient to participate.
研究者
相似试验
进行中（未招募）
不适用
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Lipid-Altering Efficacy, Safety and Tolerability of MK-0524A in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia - MK-0524A Lipid/Flushing StudyHypercholesterolaemiaMedDRA version: 8.0Level: LLTClassification code 10020603EUCTR2005-005093-70-ATMerck Sharp & Dohme GesmbH1,620
已完成
不适用
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Long-term Efficacy, Safety and Tolerability of ERN/LRPT in Patients With Dyslipidemia-E78 Disorders of lipoprotein metabolism and other lipidaemiasDisorders of lipoprotein metabolism and other lipidaemiasE78PER-108-09MERCK SHARP & DOHME PERU S.R.L.,
进行中（未招募）
不适用
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Extended-Release (ER) Niacin and Laropiprant (ERN/LRPT) in Patients with DyslipidemiaDyslipidemiaMedDRA version: 12.0Level: LLTClassification code 10058108Term: DyslipidaemiaEUCTR2009-012772-27-DKMerck & Co., Inc.1,125
进行中（未招募）
不适用
A worldwide placebo-controlled study to evaluate the additional lipid benefits of extended release (ER) niacin/laropiprant when taken with current lipid-modifying therapy in individuals with abnormal lipidsPrimary Hypercholesterolemia or Mixed DyslipidemiaMedDRA version: 14.1Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861MedDRA version: 14.1Level: LLTClassification code 10058110Term: DyslipidemiaSystem Organ Class: 100000004861EUCTR2010-021627-27-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.1,224
进行中（未招募）
不适用
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Extended-Release (ER) Niacin and Laropiprant (ERN/LRPT) in Patients with DyslipidemiaDyslipidemiaMedDRA version: 12.0Level: LLTClassification code 10058108Term: DyslipidaemiaEUCTR2009-012772-27-FIMSD Finland Oy1,125